Blood Culture Test Market revenue to cross USD 22 Billion by 2035, says Research Nester
November 13, 2023 07:00 ET
|
Research Nester
New York , Nov. 13, 2023 (GLOBE NEWSWIRE) -- The global blood culture test market size is slated to expand at 11.90% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 22...
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
May 15, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present at Cantor Antibiotics Summit
January 11, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
May 25, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
April 19, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - April 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at Biotech Showcase 2017 Conference
January 04, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - January 04, 2017) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
November 17, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 17, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at The Lysin Meeting
November 10, 2016 16:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 10, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
November 09, 2016 16:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 09, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...